Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $376
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Sell rating on Vertex Pharmaceuticals (NASDAQ:VRTX) but raises the price target from $371 to $376.
July 31, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a Sell rating on Vertex Pharmaceuticals but raises the price target from $371 to $376.
The Sell rating suggests a negative outlook, but the raised price target indicates some positive expectations. The mixed signals likely result in a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100